Brazil Biosurgery Market Overview, 2031

Key Insights

• The Brazil biosurgery market represents the largest and most dynamic national market for surgical biomaterials in Latin America. The market encompasses a broad range of biologically derived and bio-compatible materials including hemostatic agents, surgical sealants and adhesives, bone-graft substitutes, adhesion barriers, soft-tissue attachments, and staple-line reinforcement products that assist in surgical procedures by controlling bleeding, sealing tissues, promoting regeneration, and preventing postoperative complications.
• The Brazil biosurgery market is distinguished by its vast healthcare system, immense surgical volumes, and rapidly evolving regulatory environment. According to the Ministry of Health, the Unified Health System (SUS) recorded 13,663,782 elective surgeries in 2024, the highest number in history, representing a 10.8% increase from 2023 and a 30% increase from 2022. In 2025, SUS performed 14.7 million surgeries, setting another record. Total health expenditure in Brazil reached approximately 9.5% to 10% of GDP in 2025, with projections of R 1202 trillion. The medical technology market in Brazil generated approximately R 80 billion (USD 15.5 billion) in apparent consumption in 2025. The market is shaped by a complex interplay of demographic trends, technological innovation, regulatory frameworks, and evolving healthcare delivery models.
• Bone-Graft Substitutes represent the largest product category within the Brazilian biosurgery market, driven by the high volume of orthopedic and trauma procedures. Brazil's rapidly aging population and high incidence of road traffic accidents continue to drive demand for musculoskeletal interventions. Surgical Sealants and Adhesives represent the fastest-growing product category, driven by increasing adoption of minimally invasive surgical techniques. Brazil is witnessing a rapid shift toward laparoscopic and endoscopic surgeries, with the Brazilian robotics surgery market having grown 417%.
• Brazil's aging population represents a significant long-term demand driver. As of 2025, 16.6% of the population (approximately 35.3 million people) were aged 60 years or older, up from 11.3% in 2012. The population aged 50-59 increased from 10% to 11.8%. The regulatory environment, centered on the Brazilian Health Regulatory Agency (ANVISA), plays a decisive role in shaping market dynamics. In 2025, ANVISA processed 10,639 new registration records, the highest annual total in the agency's history, representing a 16.2% year-over-year increase.
Market Outlook
• According to the research report, "Brazil Biosurgery Market Overview, 2031 Overview, 2031," published by Bonafide Research, the Brazil Biosurgery market is anticipated to grow at more than 6% CAGR from 2026 to 2031.
• The Brazilian biosurgery market is expected to maintain robust growth through 2031, supported by favorable demographic trends, ongoing technological innovation, expanding surgical volumes, and government policies promoting healthcare access. Brazil's healthcare expenditure continues to rise, reaching approximately 9.5% to 10% of GDP in 2025. The medical technology market in Brazil generated approximately R$ 80 billion (USD 15.5 billion) in 2025, with 7% growth in apparent consumption of medical devices. In 2024, the Brazil medical devices market was valued at USD 15.28 billion. This substantial healthcare investment provides the financial foundation for sustained surgical activity and biosurgical product utilization.
• The aging Brazilian population represents the most significant long-term demand driver. As of 2025, 16.6% of the population (approximately 35.3 million people) was aged 60 years or older, a 5.3 percentage point increase from 2012. The population aged 50-59 increased from 10% to 11.8%, and those aged 40-49 from 13% to 15%. This demographic shift will drive increased demand for orthopedic, cardiovascular, and other surgical interventions.
• Technological innovation in biomaterials and surgical delivery systems is expanding the addressable market. Brazil is witnessing a rapid shift toward laparoscopic and endoscopic surgeries. The Brazilian robotics surgery market has grown 417%, driven by technological advancements and regulatory frameworks that support innovation.
• Rising surgical procedures and expanding healthcare access are key drivers propelling market expansion. SUS performed 14.7 million surgeries in 2025, setting a new record. The private healthcare sector also shows significant growth, with Rede D'Or reporting surgical volume increasing to 157,000 procedures (+21.3% YoY) in Q3 2025.

Market Dynamics



Driver: Massive and Growing Surgical Volumes Across All Specialties
Brazil performs tens of millions of surgical procedures annually across its vast network of public and private hospitals. According to the Ministry of Health, SUS recorded 13,663,782 elective surgeries in 2024, the highest number in history, representing a 10.8% increase from 2023 and a 30% increase from 2022. In 2025, SUS performed 14.7 million surgeries, setting another record. The private healthcare sector also shows significant growth, with Rede D'Or reporting surgical volume increasing to 157,000 procedures (+21.3% YoY) in Q3 2025. Bariatric surgeries in Brazil reached 291,731 procedures between 2020 and 2024. The breadth and depth of surgical activity in Brazil ensure that biosurgical products particularly hemostatic agents and sealants are utilized in virtually every operating room. Total health expenditure of 9.5% to 10% of GDP provides the financial infrastructure to support expanding surgical volumes. The continued expansion of surgical capacity, driven by hospital modernization and the growing network of healthcare facilities, further reinforces this demand driver.

Challenge: Healthcare Spending Constraints and Regulatory Complexity
Despite the market's enormous size and growth potential, Brazil faces significant challenges that affect the biosurgery market. Total health expenditure, while substantial, faces constraints from macroeconomic conditions and limitations in health system financing. The public health system (SUS) faces significant waiting lists, with only a fraction of the population with medical indications for certain procedures able to access them. For bariatric surgery, less than 1% of the population with medical indication is able to undergo the procedure. The regulatory environment adds complexity ANVISA's registration process for higher-risk medical devices (Classes III and IV) requires comprehensive technical and clinical data submissions, Good Manufacturing Practices certification, and conformity assessments. The agency's resources have remained practically unchanged for a decade despite ascending technological complexity. Additionally, the private healthcare sector has experienced consolidation pressures, with larger hospital groups acquiring smaller facilities.

Trend: Accelerating Regulatory Modernization and Technology Adoption
The Brazilian biosurgery market is experiencing significant transformation driven by regulatory modernization and rapid technology adoption. In 2025, ANVISA processed 10,639 new registration records, the highest annual total in the agency's history and a 16.2% year-over-year increase. On December 17, 2025, ANVISA published a new manual for medical device registration, updating requirements based on RDC 751/2022. The regulatory framework distinguishes between notification for lower-risk devices (Classes I and II) and full registration for higher-risk devices (Classes III and IV). Brazil is witnessing a rapid shift toward laparoscopic and endoscopic surgeries. The Brazilian robotics surgery market has grown 417%, with robotic surgical systems classified as Class III under ANVISA regulations. The adoption of advanced surgical platforms creates new opportunities for biosurgical products specifically designed for minimally invasive and robotic procedures.

Policies

• The Brazilian Health Regulatory Agency (ANVISA) serves as the primary regulatory authority for medical devices in Brazil. In 2025, ANVISA processed 10,639 new registration records, the highest annual total in the agency's history, representing a 16.2% year-over-year increase.
• RDC 751/2022 establishes the risk classification system, notification and registration regimes, and labeling and use instructions requirements for medical devices in Brazil.
• Medical devices are classified into four risk categories: Classes I and II (low and medium risk) are subject to prior notification, while Classes III and IV (high and maximum risk) require full registration with ANVISA.
• Class III and IV device registration requires a comprehensive technical dossier, performance and biocompatibility data, clinical evaluation, and Good Manufacturing Practices certification.
• The Unique Device Identification (UDI) system was consolidated in Brazil through RDC 591/2021. In 2025, ANVISA presented the UDI system and regulatory updates for medical devices.
• ANVISA's Innovation Policy (Portaria 1,100/2023) and the Economic-Industrial Health Complex guidelines (Decreto 11,464/2023) support innovative medical device regulation.

Segment Analysis

Brazil Biosurgery Market By Product
• Bone-Graft Substitutes represent the largest product category within the Brazilian biosurgery market, driven by the high volume of orthopedic and trauma procedures. Brazil's aging population with 16.6% aged 60 and older continues to drive demand for musculoskeletal interventions. These products include demineralized bone matrix (DBM), synthetic bone grafts, and biologic grafts incorporating growth factors, widely utilized in trauma fixation, spinal fusion, and joint replacement procedures.
• Hemostatic Agents constitute a major market segment, reflecting their essential role across all surgical disciplines. These products including topical hemostats, flowable matrices, fibrin sealants, and thrombin-based agents are utilized in virtually every surgical procedure to control intraoperative bleeding. With SUS performing 14.7 million surgeries in 2025 and private hospitals also showing significant volumes, demand for hemostatic products is substantial and growing.
• Surgical Sealants and Adhesives represent the fastest-growing product category in the Brazilian biosurgery market, driven by increasing adoption of minimally invasive surgical techniques. These products including fibrin sealants, synthetic polymer-based sealants, and protein-based adhesives are used to seal tissue surfaces, prevent fluid and air leaks, and reinforce surgical anastomoses. Brazil is witnessing a rapid shift toward laparoscopic and endoscopic surgeries, supporting the expansion of this segment.
• Adhesion Barriers represent a clinically important product category used to prevent postoperative adhesion formation in abdominal, pelvic, and gynecological surgeries. The category continues to benefit from ongoing product innovation and clinical evidence supporting adhesion prevention, particularly as the volume of gynecological and abdominal procedures remains substantial.
• Soft-Tissue Attachments encompass products used to reinforce, repair, or secure soft tissues, including surgical meshes, biologic scaffolds, and tissue grafts. These products are utilized in hernia repair, pelvic floor reconstruction, and various other soft-tissue procedures supported by high procedure volumes in Brazilian hospitals.
• Staple-Line Reinforcement products are utilized in gastrointestinal, bariatric, and thoracic procedures to strengthen tissue interfaces along surgical staple lines. Brazil performed 291,731 bariatric surgeries between 2020 and 2024, supporting demand for these products.

Brazil Biosurgery Market By Application
• Orthopedic Surgery is the largest application area for biosurgical products in Brazil, driven by the high volume of trauma surgeries, joint replacements, and spinal procedures. Brazil's aging population with 16.6% aged 60 and older continues to drive demand for musculoskeletal interventions. The Brazilian Society of Orthopedics and Traumatology (SBOT) represents the specialty.
• General Surgery encompasses a broad range of abdominal, gastrointestinal, and soft-tissue procedures, including bariatric surgery, colorectal surgery, and hernia repair. SUS performed 14.7 million surgeries in 2025. Bariatric surgeries reached 291,731 procedures between 2020 and 2024. The private sector performed significantly higher rates of many general surgical procedures.
• Cardiovascular Surgery represents the fastest-growing application area in the Brazilian biosurgery market, driven by the high prevalence of cardiovascular disease and the aging population. The Brazilian Journal of Cardiovascular Surgery reports that the average number of cardiac surgeries performed in Brazil is approximately 100,000 annually, most consisting of myocardial revascularization and valve surgery. Transcatheter aortic valve implantation (TAVI) has been established as the treatment of choice for severe aortic stenosis.
• Neurological Surgery utilizes biosurgical products particularly hemostatic agents and dural sealants to manage bleeding and prevent cerebrospinal fluid leaks in cranial and spinal procedures. The aging population and increasing incidence of neurological conditions drive demand in this specialty.
• Reconstructive Surgery involves the use of biosurgical products to restore, repair, or reconstruct damaged or surgically altered tissues. SUS performed 716,000 reconstructive plastic surgeries in the last five years, with 108,280 procedures performed in 2025 and 174,757 in 2024.
• Gynecological Surgery includes biosurgical applications in procedures involving the female reproductive system, with products used for hemostasis, tissue sealing, adhesion prevention, tissue repair, and reinforcement.
• Urological Surgery covers biosurgical applications in procedures involving the urinary tract and male reproductive system, with products used for bleeding control, tissue sealing, reinforcement, repair, and prevention of postoperative complications.
• Thoracic and Other Surgeries represent a growing application area, driven by increasing adoption of video-assisted thoracoscopic surgery (VATS) and the rising burden of lung cancer and other thoracic conditions.

Brazil Biosurgery Market By Source/Origin
• Biologic products represent the largest source category in the Brazilian biosurgery market, driven by their superior biocompatibility and natural healing properties. These products include demineralized bone matrix, fibrin sealants, collagen hemostats, allografts, and xenografts. ANVISA's rigorous requirements for biological materials ensure high safety standards and support market confidence.
• Synthetic and Semi-Synthetic products represent the fastest-growing source category in the Brazilian market, driven by cost-effectiveness, consistent quality, lower immunogenicity risks, and longer shelf life. These products include synthetic bone substitutes, PEG-based sealants, synthetic meshes, and polysaccharide hemostats. The Brazilian healthcare system's emphasis on cost-effectiveness and the growing domestic manufacturing sector favor synthetic alternatives for certain applications.

Brazil Biosurgery Market By End-User
• Hospitals remain the largest end-user segment for biosurgical products in Brazil, accounting for the majority of revenue. Public hospitals under SUS perform the majority of surgical procedures, with 14.7 million surgeries in 2025. Private hospitals also represent a significant segment, with Rede D'Or reporting surgical volume of 157,000 procedures (+21.3% YoY) in Q3 2025. The concentration of complex surgical procedures and availability of specialized surgical teams make hospitals the primary setting for biosurgical product utilization.
• Ambulatory Surgical Centers (ASCs) represent the fastest-growing end-user segment in the Brazilian biosurgery market, driven by the broader healthcare industry shift toward outpatient and same-day discharge models. The expansion of outpatient surgical capacity, supported by both public and private healthcare sectors, supports the adoption of biosurgical products in these settings.
• Clinics represent a growing end-user segment, with specialty clinics performing eligible surgical or minimally invasive procedures utilizing biosurgical products for tissue repair, bleeding control, and sealing.

Brazil Biosurgery Market Economics

• Brazil’s biosurgery market operates through the public Unified Health System (SUS) and a large private healthcare sector. Healthcare expenditure was approximately 9.5–10% of GDP in 2025, while the medical technology market generated around R$80 billion (USD 15.5 billion). Manufacturers face pricing pressure and must navigate public tenders, private hospital agreements, and surgeon preferences. Consolidated procurement is increasing competition, while local manufacturers are gaining market share.
• Brazil has a vast healthcare infrastructure across 26 states and the Federal District. SUS performed a record 14.7 million surgeries in 2025, while private providers also recorded strong growth, with Rede D’Or performing about 157,000 procedures. A growing physician and specialist workforce supports expanding surgical capacity, although specialists remain more concentrated in private healthcare. Brazil’s large patient population and extensive hospital network provide a strong foundation for biosurgery demand.
• Innovation and technology adoption are major growth drivers. The Brazilian medical devices market is projected to increase from USD 16.15 billion in 2025 to USD 25.00 billion by 2032. Robotic surgery, minimally invasive procedures, laparoscopy, endoscopy, and advanced biomaterials are expanding rapidly, with the robotics surgery market reportedly growing 417%. ANVISA’s Innovation Policy and Economic-Industrial Health Complex initiatives further support medical technology development and investment.
• Brazil’s long-term biosurgery outlook remains highly positive, supported by its 212.7 million population, an ageing demographic, expanding surgical volumes, and technological advancement. Around 16.6% of the population is aged 60 or older, creating increasing demand for surgical care. The biosurgery market is expected to grow at more than 6% CAGR from 2026–2031. However, manufacturers must successfully manage ANVISA regulations, pricing pressures, procurement complexity, and competition to capture market opportunities.


Considered in this report
• Historic Year: 2020
• Base year: 2025
• Estimated year: 2026
• Forecast year: 2031

Aspects covered in this report
• Biosurgery Market with its value and forecast along with its segments
• Various drivers and challenges
• On-going trends and developments
• Top profiled companies
• Strategic recommendation

By Product
• Bone-Graft Substitutes
• Hemostatic Agents
• Surgical Sealants & Adhesives
• Adhesion Barriers
• Soft-Tissue Attachments
• Staple-Line Reinforcement

By Application:
• Orthopedic Surgery
• General Surgery
• Neurological Surgery
• Cardiovascular Surgery
• Reconstructive Surgery
• Gynecological Surgery
• Urological Surgery
• Other surgeries (Thoracic surgeries & more)

By Source/Origin
• Biologic
• Synthetic / Semi-synthetic

By End-user:
• Hospitals
• Ambulatory Surgical Centers
• Clinics
• Others